Tumor Necrosis Factor Inhibitor Drugs Market Report

Tumor Necrosis Factor Inhibitor Drugs Market Analysis, Market Size, Product Analysis, Regional Outlook, Competitive Strategies, And Segment Forecasts, 2019 To 2026

  • Published Date: ---
  • Base Year for Estimate: ---
  • Report ID: GVR5906
  • Format: Electronic (PDF)
  • Historical Data: ---
  • Number of Pages: 0

The global tumor necrosis factor (TNF) inhibitor drugs market is projected to exhibit moderate growth through the forecast period, driven by the emergence of biosimilars and rising incidence of autoimmune diseases. The therapeutic landscape faces intense competitive rivalry – both internally and externally.

TNF is a cytokine activator for multiple pathways, including MAPK and NFkB pathway, leading to a production cascade of other cytokines as well as TNF-induced apoptosis. Excess TNF is blocked in healthy individuals, but rheumatically affected people tend to overproduce TNF causing inflammatory reactions. Most of these conditions are autoimmune disorders. TNF inhibitors or blockers are anti-inflammatory drugs, designed to stop TNF overproduction.

The TNF inhibitors drugs market is segmented by products. Currently, there are five approved TNF inhibitors: adalimumab, etanercept, infliximab, golimumab, and certolizumab. Although the products continue to generate high commercial sales, patent expirations have driven the emergence of biosimilars. In addition, the impending launch of pipeline candidates is a potent growth driver for this market.

The TNF inhibitors drugs market is further on the basis of applications into the following: rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, juvenile idiopathic arthritis, and hidradenitis suppurativa. Based on sales channel, the market is classified into hospital pharmacies, retail pharmacies, and online pharmacies. Geographically, the market has been divided into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa

Some of the major players in the global tumor necrosis factor inhibitor drugs market include AbbVie, Inc.; Amgen, Inc.; Johnson & Johnson Services, Inc.; Novartis International AG; Pfizer, Inc.; and UCB S.A., Samsung Bioepis Co. Ltd., and Boehringer Ingelheim Pharmaceuticals, Inc.

Key questions answered by the report
Request for Customization

Choose License Type

Single User - $4,950
Multi User (2-5) - $5,950
Enterprise Access - $7,950

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert.

  • Custom research service

    Custom research service

    Design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • grand view research PCI DSS complaint grand view research paypal verified